Invasive fungal infections (IFIs) are major complications after allogeneic hematopoietic SCT (HSCT). PCR-based assays able to detect fungal DNA have been reported to precede clinical diagnosis of IFI. We performed a prospective study to evaluate a PCR-based pre-emptive approach. Ninety-nine patients undergoing reduced-intensity conditioning (RIC) HSCT were followed with fungal PCR during the first 100 days post transplantation. Patients who tested positive were randomized to receive liposomal amphotericin B, or to no intervention. After day 100, PCR tests were performed only on clinical suspicion of IFI. A single positive PCR test was not associated with IFI, irrespective of treatment. After day 100, PCR tests for Aspergillus did not contribute to diagnosis of invasive aspergillosis (IA). The cumulative incidence rates of proven or probable IA during the first year after transplantation were 9%. GVHD grades II-IV (P ¼ 0.0014), CMV-seronegative recipient with CMVseropositive donor (Pp0.001), and conditioning with alemtuzumab (P ¼ 0.014) were significant risk factors for developing IA in a multivariate model. In this study, PCR on peripheral blood was a poor indicator of IFI early after RIC HSCT. Aspergillus PCR tests performed on clinical suspicion after day 100 were insufficiently sensitive to be diagnostically useful.
Introduction
Invasive fungal infections (IFIs) are major complications after allogeneic hematopoietic SCT (HSCT). IFIs have a high attributable mortality despite appropriate antifungal treatment. [1] [2] [3] [4] Non-myeloablative or reduced-intensity conditioning (RIC) results in less severe mucositis and a shorter period of neutropenia after HSCT. This has reduced the incidence of early bacterial infections, but some studies have shown that the incidence of IFI after RIC is the same or even higher than with myeloablative regimens. [5] [6] [7] [8] [9] A possible explanation for this may be that RIC enables older patients and patients with co-morbidities to be transplanted. 10 A problem in the management of IFI is the difficulty in ascertaining the diagnosis early enough for successful intervention. 1, 4, 11 Blood cultures for Candida have poor sensitivity. 12 A definitive diagnosis of mold infections depends on invasive procedures that allow visualization of hyphae in tissue or a positive culture from sterile sites. 13 Such procedures are often not feasible in HSCT patients because of severe thrombocytopenia. In recent years, noninvasive diagnostic techniques such as PCR-based assays capable of detecting DNA from Aspergillus and Candida species have been developed. [14] [15] [16] [17] [18] [19] Several PCR protocols for detection of fungal DNA in blood have been used, with a wide range of sensitivity and specificity. Although the results have been variable, the authors of some of these reports have concluded that PCR contributes to establishment of the diagnosis of IFI. [15] [16] [17] It has also been reported that a positive PCR test precedes the clinical diagnosis of invasive aspergillosis (IA), by several days up to several weeks. 15, 16 These findings raise the question of whether PCR-guided early antifungal treatment could reduce the incidence and mortality of IFI after HSCT, in an analogous way to the successful development of pre-emptive treatment of CMV. 20 To answer this question, we performed a prospective study in which patients with a positive fungal PCR result within 100 days of RIC HSCT were randomized to receive either treatment with liposomal amphotericin B or no treatment.
Materials and methods

Patients
All patients undergoing HSCT after RIC at the Karolinska University Hospital, Huddinge, between April 2002 and November 2006 were eligible for inclusion, the only exclusion criterion being hypersensitivity to liposomal amphotericin B. In total, 99 patients were included; detailed characteristics are given in Table 1 . The study was approved by the Research Ethics Committee of Karolinska Institute (DNR 383/01, 20011105) and written consent was obtained from all patients.
Study design
Patients were followed once a week with fungal PCR for the first 100 days after transplantation. Patients with a positive PCR result were randomized to antifungal treatment with liposomal amphotericin B (Ambisome, Swedish Orphan, Stockholm, Sweden) 21, 22 or to no treatment. Liposomal amphotericin B was given at a dose of 3 mg/kg/day for patients with positive PCR for Aspergillus. After 3 days, the dose was reduced to 1 mg/kg/day if the patient was in a stable clinical condition. For Candida the treatment dose was 1 mg/kg/day. The treatment was continued until one PCR test was found to be negative in patients without fever and neutropenia, or until two consecutive PCRs were negative in patients with fever and/or neutropenia. Depending on the patient's clinical status, the treatment could be prolonged according to the judgment of the treating physician. Patients with fever above 38.5 1C for 3 days despite treatment with antibiotics, and with unknown etiology, were considered eligible for antifungal treatment regardless of the PCR results. The primary endpoint was success of PCR-guided antifungal treatment defined as a reduction of proven and probable IFIs in patients allocated to liposomal amphotericin B treatment within 100 days of HSCT. Secondary endpoints were survival at 100 days and at 1 year, 1-year incidence of IFI, and risk factors for IFI.
Procedures
All patients received fludarabine (30 mg/m 2 /day) for 5-6 days in combination with various additional treatments such as 2 Gy TBI (n ¼ 1), 2 Â 3 Gy fractionated TBI and 60 mg/kg CY (n ¼ 13), BU 8 mg/kg (n ¼ 49), 120 mg/kg CY (n ¼ 30), or treosulphan (n ¼ 5). 10, 23 Most patients (n ¼ 85) received anti-T-cell therapy during the conditioning: either anti-thymocyte immunoglobulin (ATG) (n ¼ 69) or alemtuzumab (Mab-Campath; Bayer, Leverkusen, Germany) (n ¼ 16). Two types of ATG were used; 66 patients received thymoglobulin (4-8 mg/kg) (Genzyme; Cambridge, MN, USA) and 3 patients received ATGFresenius (30 mg/kg) (Fresenius; Gra¨felfing, Germany).
The majority of patients received CsA and MTX as prophylaxis against GVHD. 24 In the absence of GVHD, CsA was discontinued after 4-6 months. Acute GVHD (aGVHD) was diagnosed on the basis of clinical symptoms and/or biopsies according to standard criteria. The patients were treated for grade I aGVHD with prednisolone, starting at 2 mg/kg/day, which was tapered after the initial response. 24 In more severe cases, ATG, methylprednisolone, MTX, psoralene and UV light (PUVA), or mesenchymal stem cells were used.
All patients were treated in HEPA-filtered rooms or in their own home during neutropenia (median duration 18 days, range 0-50). Non-absorbable amphotericin B (n ¼ 51) or fluconazole 100 mg once daily (n ¼ 46) was administrated orally from the start of conditioning. When the ANC reached 0.5 Â 10 9 /l, this fungal prophylaxis was discontinued. Oral nystatin (200 000 IE) was given four times a day from the day of transplantation and was continued for 3 months. Voriconazole was used as secondary prophylaxis for two patients with suspected IA before the transplantation. Bacterial prophylaxis with 500 mg ciprofloxacin twice a day was started 1 day before transplantation and continued until ANC 40.5 Â 10 9 /l. Acyclovir prophylaxis was only used in patients who had an IgG antibody titer to herpes simplex virus of X10 000 and it was administered until ANC 40.5 Â 10 9 /l. 25 Prophylaxis for Pneumocystis jiroveci pneumonia using co-trimoxazole (or inhalation of pentacarinat in patients who did not tolerate co-trimoxazole) was prescribed for at least 6 months after HSCT.
Asymptomatic CMV viremia, diagnosed by CMV PCR, was treated pre-emptively using intravenous or oral valganciclovir. 26 If this therapy failed, the patients were switched to treatment with foscarnet.
Fungal PCR
Fungal PCR was performed once a week in whole-blood samples with EDTA (5 ml) for the first 100 days post transplantation. After that, PCR was performed only on clinical suspicion of IFI. All the samples were analyzed at the Division of Clinical Bacteriology, Department of Laboratory Medicine, Karolinska University Hospital. A real-time PCR assay described by Klingspor and Jalal 19 was used. In that study in vitro testing showed the assay to detect clinically relevant Aspergillus and Candida spp. with a sensitivity of 2 CFU/ml blood with a 100% amplification specificity. 19 Briefly, DNA was extracted from blood samples using a manual extraction method in combination with a fully automated laboratory robot, the MagNA Pure LC instrument. The primers and hybridization probes for Candida spp. were developed by Klingspor and Jalal 19;  the Aspergillus probe was that described by Loeffler et al. 27 The LightCycler system (Roche, Basel, Switzerland) was used for PCR amplification and detection with a cut-off value at 40 cycles. Each PCR analysis included a negative control consisting of hypotonic red cell lysis buffer, an extraction control, and a positive control containing fungal DNA.
The following precautions were taken to avoid contamination: before analysis was performed, cabinets, pipettes, racks, and DNA extraction robots were wiped down with a DNAzap (Ambion, Warrington, UK). Each stage was carried out in separate laboratories that were independently equipped. Both the manual steps and the robot extraction of DNA were performed in a special room in the lab with overpressure and hepafiltered incoming air. Filter tips were used on the pipettes, DNA grade water was used and one negative control was added for every five clinical samples.
Definitions IFI was classified as probable or proven according to the European Organization for Research and Treatment of Cancer/Mycosis Study Group (EORTC/MSG) criteria. 13 Briefly, proven disease required histopathological or microbiological documentation of fungal infection from biopsy tissues. Infection was considered probable if the fungus was identified in bronchoalveolar lavage or sputum and the patient had consistent clinical findings on thoracic CT imaging.
Species identification in patient with proven invasive mold infection at autopsy was done with culture and/or immunhistochemistry. 28 
Statistical analysis
Patients were censored at the time of death or last follow-up. The incidence of IA was estimated using a non-parametric estimator of cumulative incidence curves. 29 Predictive analyses were based on the proportional hazards model for subdistribution of competing risk. Death without IA within 1 year of HSCT was the competing event. Univariate and multivariate analyses were then performed using Gray's test, and the proportional sub-distribution hazards regression model developed by Fine and Gray. 30 A stepwise backward procedure was used to construct a set of independent predictors for each endpoint. All predictors with a P-value of o0.10 were considered and sequentially removed if the Pvalue in the multiple model was above 0.05. All tests were two-sided. The type I error rate was fixed at 0.05 for factors potentially associated with time-to-event outcomes. Factors analyzed in the univariate analysis included patient and donor sex and age, sex-mismatch, diagnoses (lymphoma vs others), disease stage, conditioning (busulphan vs TBIbased), stem cell source, ABO blood group match, G-CSF, CMV serology, nucleated and CD34 þ cell dose, ATG type (alemtuzumab vs others), CMV infection and disease, and GVHD. Time-dependent factors such as GVHD, CMV infection, and disease were only analyzed if they occurred before IA. Analyses were performed using the cmprsk package (developed by Gray, June 2001), Splus 6.2 software, and Statistica software.
Results
Incidence of IFI
The cumulative incidence rates of proven or probable IFI, IA, and invasive candidiasis during the first year after transplantation were 12, 9, and 2%, respectively.
Seven patients had autopsy-proven IA; details of these cases are presented in Table 3 . Two patients were diagnosed with probable aspergillosis based on CT findings combined with growth of A. fumigatus from sputum. One patient had CT findings and hyphae in sputum consistent with probable mold infection, but with negative culture.
Median time to onset of IA was 192 days (range 21-282) after transplantation. Only two cases were diagnosed before day 100 and six cases were diagnosed more than 6 months after transplantation (Figure 1) .
Two patients were diagnosed with candidemia, both before day 100 after HSCT. One patient had a catheter-related candidemia while in ICU, with growth of C. albicans, and one patient had growth of C. glabrata in blood cultures without known focus. Both patients were receiving fluconazole prophylaxis, 100 mg, at the time of diagnosis.
PCR tests and therapy
Ninety-six of the 99 patients included could be evaluated; 2 patients were transferred to other hospitals and 1 patient chose to leave the study.
A median of 14 PCR tests (range 4-18) was taken per patient during the first 100 days after transplantation. The number of tests performed in patients with negative PCR results did not differ from the number in patients with positive PCR results. Out of PCR tests taken during neutropenia, 5.9% (21/353) were positive and after resolution of neutropenia, 4.2% (39/923).
Forty-one patients had at least one positive PCR result (Aspergillus, n ¼ 18; Candida, n ¼ 29; both, n ¼ 6), but only 21 patients (51%) were randomized. The most important reason for not randomizing patients was reluctance of the treating physician to expose well-feeling, asymptomatic outpatients to a drug requiring intravenous administration, and hospitalization. Instead the PCR test was repeated, with negative result in all 20 patients.
Thirteen patients were allocated to no treatment, but one patient received treatment with liposomal amphotericin B because of clinical suspicion of IFI (did not fulfill IFI criteria) and one patient received voriconazole because of growth of Penicillium in the bronchoalveolar fluid.
There were no significant differences in incidence of proven or probable IFI between the patients who were randomized to treatment (0 IFI/8 patients) and those who were randomized to no treatment (1 IA/13 patients).
PCR tests and IFI within 100 days of HSCT
The number of positive PCR tests within 100 days of HSCT and the relation to fungal treatment or prophylaxis and proven or probable IFI are shown in Table 2 . A single positive PCR result was not associated with IFI. Owing to the low numbers, no conclusions could be drawn regarding multiple positive PCR tests and a possible association with IFI. Three of the four patients with IFI within 100 days of HSCT (one proven candidiasis, one proven IA, and one probable IA) had consecutive negative PCR tests.
PCR test for Aspergillus did not contribute to diagnosis of IA After the first 100 days post transplantation, fungal PCR was performed on clinical suspicion of IFI. Six of nine patients with proven or probable IA had at least one Aspergillus PCR test performed during the 2 weeks preceding the date of diagnosis. None of these patients received antifungal treatment when the samples were taken. One patient had one positive and one negative result; the other five patients had negative results, including two patients with autopsy-proven disseminated IA (Table 4) .
Risk factors for IA
Univariate analysis revealed that aGVHD grades II-IV, CMV-seronegative recipient, and CMV disease were associated with increased risk of IA (Table 3) . In a multivariate model, significant risk factors were aGVHD grades II-IV (relative hazard 13.1, 95% confidence interval 2.20-77.5, (Figures 2a and b) . During the first year after transplantation no cases of IA were diagnosed in patients without the risk factors identified in the multivariate model. Patients with one risk factor had a cumulative incidence of IA of 7.9%, with two risk factors the incidence increased to 72% (Figure 2c ).
Outcome
The cumulative 1-year mortality was 31% (32/99 patients).
An autopsy was performed in 14 cases (44%), and showed evidence of IA in seven patients ( Table 4) . The 1-year survival after diagnosis of IA was 22%. IA was considered to be the main or contributing factor in 6/15 patients (40%) who died from transplant-related causes and in 6/32 patients (19%) who died in the first year after transplant.
Discussion
The main purpose of this study was to determine whether PCR-guided early therapy with liposomal amphotericin B reduces the incidence and mortality of IFI. Unfortunately, this question could not be addressed properly because of flawed randomization and low incidence of IFI in the first 100 days after transplantation. The reluctance to randomize patients was mainly because of an unwillingness to expose well-feeling, asymptomatic outpatients to a drug requiring intravenous administration, and hospitalization. An oral drug with Aspergillus activity, such as voriconazole, would have been preferred but was not available when this study was initiated. The treating physicians preferred to perform a new PCR test that turned out negative in all 20 patients that were not randomized. As none of these patients developed an IFI this strategy turned out successful. The clinical pertinence of screening with fungal PCR for early diagnosis of IFI was not fully addressed because of the low incidence of IFI during the first 100 days after transplantation. To answer the question of whether a pre-emptive approach using monitoring with fungal PCR tests is feasible, a study over a prolonged period after HSCT will be needed. However, the shift to a later onset of IA after HSCT with RIC, which was not known at the start of this study, makes a pre-emptive approach using regularly performed fungal PCR tests less attractive because of the negative findings in this study and the large number of tests required.
A substantial number of episodes with a single positive PCR result (41) occurred in 36 patients classified as not having IFI. This finding is consistent with earlier reports in which a single positive PCR test did not correlate with proven or probable fungal disease and resolved without treatment. 31, 32 One possible explanation is laboratory contamination that is hard to eliminate even though extensive precautions were used. Another possible reason for false positive Aspergillus PCR was recently reported to be contaminated nutritional supplement. 33 However, as PCR does not differentiate between living and dead fungus, a single positive PCR test could represent a true, early stage, of fungal infection that the immune system of the patient has been able to take care of on its own. Early implementation of antifungal treatment because of fast access to CT scan and access to an effective oral drug (voriconazole) makes achieving definite proof of IA more difficult. In addition, there have been several reports of antifungal treatment being associated with conversion of PCR test results from positive to negative. 18, 31, 32 These findings may partly explain the many single positive PCR tests for Candida in this study, as many of these patients received prophylaxis with fluconazole. However, the single positive PCR tests for Aspergillus are difficult to explain because only 4 of these 15 patients received active treatment or prophylaxis against Aspergillus. In this study, a single positive PCR test for Aspergillus during the first 100 days after transplantation had no correlation with IA.
Several investigators have reported better results using two or more positive tests to define PCR positivity, yielding sensitivities between 64 and 100% and specificities between 70 and 90%. 15, 17, 34 No conclusions regarding multiple [15] [16] [17] 34, 35 In our study, we did not find that PCR tests for Aspergillus were useful in patients with proven or probable IA. Fungal PCR tests were performed within 2 weeks of diagnosis in six of nine patients with proven or probable IA, and only one patient had a positive PCR test.
We used the EORTC/MSG definitions from 2001 because the collection of data and analysis was done before the new definitions were published in September 2008. However, this had no effect on the results because applying the new definitions would not have changed any of the proven, probable, or possible cases.
In 1996, the incidence of invasive candidiasis at our institution was 5% after myeloablative HSCT. 36 Fluconazole has been used as prophylaxis since 2004 but at a lower dose: 100 mg/day instead of the dose of 400 mg/day used in the study by Slavin et al. 37 In this study, we found a cumulative 1-year incidence of invasive candidiasis of only 2%. This low incidence cannot be explained by the addition of fluconazole prophylaxis alone, because 51 patients (52%) transplanted before November 2004 received prophylaxis with only non-absorbable amphotericin B and none of these patients developed invasive candidiasis. We therefore believe that the decrease in incidence of invasive candidiasis is at least partly because of RIC. The most important factors are the shorter period of neutropenia and less severe early toxicity, leading to less mucositis using RIC as compared to myeloablative conditioning.
The 1-year incidence of proven and probable IA in our study was 9%, with the majority of cases occurring after day 100. This is in accordance with the results of several earlier publications reporting a similar incidence of IA after RIC as after myeloablative conditioning, but with a later onset. [5] [6] [7] 9, 38 aGVHD grades II-IV were a significant risk factor for development of IA in both uni-and multivariate analysis, a finding that has been well-described earlier. 5, 39, 40 Conditioning with alemtuzumab was a significant risk factor in the multivariate analysis. The initial total dose of 100 mg alemtuzumab used in HSCT was associated with a relatively high frequency of infectious complications. 41, 42 The total dose of alemtuzumab in the protocol for RIC at our institute has therefore been lowered to 30 mg. In this study three of four patients who received alemtuzumab and developed aGVHD were diagnosed with IA; the fourth died of relapse and pneumonia. No IA was diagnosed among patients receiving alemtuzumab without GVHD (n ¼ 12). The third significant risk factor in multivariate analysis was a CMVseronegative recipient transplanted with a CMV-positive donor (D þ /RÀ). Although the numbers were low, three cases of IA in 11 D þ /RÀ patients make this finding an uncertain one; the mortality in D þ /RÀ patients has been shown earlier to be associated with bacterial and fungal infections. 43 The incidence of IA was 1.9% among patients with no risk factor, increasing to 7.9% among patients with one risk factor, and reaching as high as 71.4% among patients with two risk factors. This high incidence makes a prophylaxis strategy necessary. In 2007, Ullmann et al. 44 showed that posaconazole prophylaxis to recipients of allogeneic HSCT transplants who had developed GVHD reduced IA. We therefore propose the use of posaconazole as targeted prophylaxis to RIC patients with two or more of the above risk factors.
Autopsy was performed in 14 of 15 patients with an unknown cause of death; that is not relapse or progression of their original disease. Evidence of IA was found in seven of these patients (50%) and was unexpected in three cases. This finding illustrates the difficulties in reaching the diagnosis, and the importance of autopsy rate in estimation of the incidence of IA. 3, 39 In summary, this study has shown that IA was an important complication, contributing to a substantial proportion (40%) of transplant-related mortality after allogeneic HSCT with RIC. The infection typically occurred late, 4100 days after transplantation, and significant risk factors were aGVHD grades II-IV, a CMV-seronegative recipient, and conditioning with alemtuzumab. A single positive fungal PCR test was not associated with proven or probable fungal infection during the first 100 days after RIC HSCT. In this study, analysis with Aspergillus PCR because of clinical suspicion of IA after the first 100 days did not contribute in reaching the diagnosis.
